Mediwheel <wellness@mediwheel.in>

Thu 2/22/2024 12:25 PM

To:PHC [MH-Ghaziabad] <phc.ghaziabad@manipalhospitals.com> Cc:customercare@mediwheel.in <customercare@mediwheel.in>



011-41195959

Dear Manipal Hospital

We have received a booking request for the details are following. Please provide your confirmation by clicking on the yes button.

# Are you sure to confirm the booking?

Name

: MR. SOLANKI DIGAMBER KUMAR

Package Name

: Mediwheel Full Body Health Checkup Male Above 40

Package Code

ode

Location

NH-24, Hapur Road, Oppo. Bahmeta Village, Near Lancraft Golf

Links Aparment

**Contact Details** 

: 9920542632

E-mail id

: DIGAMBER.SOLANKI@bankofbaroda.com

**Booking Date** 

: 22-02-2024

**Appointment Date** 

: 24-02-2024

Member Information						
pooked Member Name	Age	Gender				
MR. SOLANKI DIGAMBER KUMAR		Male				

Please login to your account to confirm the same. Also you mail us for confirmation

**Hospital Package** 

Name

Mediwheel Full Body Health Checkup Male Above 40

User Package Name : Mediwheel Full Body Health Checkup Male Above 40

- Stool Test
- · Thyroid Profile
- ESR
- Blood Glucose (Fasting)
- General Physician Consultation
- TMT OR 2D ECHO
- · Blood Group
- Blood Glucose (Post Prandial)
- · Chest X-ray
- ECG

# 22 Tests included in this Package

- USG Whole Abdomen
- · Eye Check-up consultation
- Urine Sugar Fasting
- Urine Sugar PP
- Dental Consultation
- Urine analysis
- CBC
- HbA1c
- · Lipid Profile
- Kidney Profile
- · Liver profile
- Prostate Specific Antigen (PSA Male)

Thanks, Mediwheel Team

You have received this mail because your e-mail ID is registered with This is a system-

because you are register with us Click here to unsubscribe.

40) 2024 - 25, Arcotomi Baalthuare Pvi Limited (Mediwheel)

#### भारत सरकार GOVERNMENT OF INDIA



दिगम्बर कुमार मोलंकी Digamber Kumar Solanki जन्म तिथि/ DOB: 18/06/1979 पुरुष / MALE

2450 9674 5878 -आम आदमी का अधिकार



#### भारतीय विशिष्ट पहचान प्राधिकरण UNIQUE IDENTIFICATION AUTHORITY OF INDIA

पताः

S/O: के. पी. एस. सोलंकी, S/O: के. पी. एस. सोलंकी, मकान न. 258, डी. एम. रोड, Uttar Pradesh - 203001 आवास विकास कॉलोनी, वुलंदशहर, बुलंदशहर, उत्तर प्रदेश - 203001

Address:

S/O: K. P. S. Solanki, House No. 258,


2450 9674 5878

-Aam Admi ka Adhikar

digamber kuman Sulanki

- NORMAL ECG -

Unconfirmed Diagnosis



# manipal hospitals



# TMT INVESTIGATION REPORT



Patient Name MR DIGAMBER KUMAR SOLANKI

Location

: Ghaziabad

Age/Sex

: 44Year(s)/male

Visit No

: V0000000001-GHZB

Order Date

: 24/02/2024

MRN No

MH011725749

Ref. Doctor : DR BHUPENDRA SINGH

Report Date

: 24/02/2024

Protocol

: Bruce

**MPHR** 

**Duration of exercise** 

: 176BPM : 149BPM

Reason for termination : THR achieved

: 10min 20sec

85% of MPHR Peak HR Achieved : 167BPM

Blood Pressure (mmHg) : Baseline BP : 140/90mmHg

% Target HR

: 94%

Peak BP : 160/90mmHg

: 12.3METS **METS** 

STAGE	TIME (min)	H.R (bpm)	BP (mmHg)	SYMPTOMS	ECG CHANGES	ARRHYTHMIA
				Nil	No ST changes seen	Nil
PRE- EXC.	0:00	56	140/90	INII	No ST energ	N. I.
STAGE 1	3:00	96	140/90	Nil	No ST changes seen	Nil
STAGE	3.00			N. I.	No ST changes seen	Nil
STAGE 2	3:00	111	150/90	Nil	No 31 changes seen	
	3:00	142	160/90	Nil	No ST changes seen	Nil
STAGE 3	3.00	142		8111	No ST changes seen	Nil
STAGE 4	1:20	167	160/90	Nil	No 31 changes seen	
			146/00	Nil	No ST changes seen	Nil
RECOVERY	4:15	93	146/88	- INII		

#### **COMMENTS:**

- No ST changes in base line ECG.
- No ST changes at peak stage.
- No ST changes in recovery.
- Normal chronotropic response.
- Normal blood pressure response.

Treadmill test is negative for exercise induced reversible myocardial ischemia. **IMPRESSION:** 

Dr. Bhupendra Singh

MD, DM (CARDIOLOGY), FACC Sr. Consultant Cardiology

Dr. Abhishek Singh

Dr. Sudhanshu Mishra

MD, DNB (CARDIOLOGY), MNAMS MD Sr.Consultant Cardiology

Cardiology Registrar

NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002

P: 0120-3535353

Page 1 of 2

Manipal Health Enterprises Private Limited

CIN: U85110KA2003PTC033055

Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017 P +91 80 4936 0300 E info@manihospitals.com www.manipalhospitals.com





NAME	MR Digamber Kumar SOLANKI	STUDY DATE	24/02/2024 11:22AM
AGE / SEX	44 y / M	HOSPITAL NO.	MH011725749
ACCESSION NO.	R6938869	MODALITY	US
REPORTED ON	24/02/2024 12:11PM	REFERRED BY	HEALTH CHECK MGD

## **USG ABDOMEN & PELVIS**

#### **FINDINGS**

LIVER: appears normal in size (measures 138 mm) and shape but shows diffuse increase in liver echotexture, in keeping with diffuse grade I fatty infiltration. Rest normal.

SPLEEN: Spleen is normal in size (measures 82 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 8 mm.

COMMON BILE DUCT: Appears normal in size and measures 3 mm.

IVC, HEPATIC VEINS: Normal. BILIARY SYSTEM: Normal.

GALL BLADDER: Gall bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Both kidneys are normal in size and shape but show raised renal cortical echotexture. Cortico-

medullary differentiation is however maintained. Rest normal.

Right Kidney: measures  $92 \times 53$  mm with parenchymal thickness 13.9 mm. Left Kidney: measures  $93 \times 49$  mm with parenchymal thickness 12.1 mm.

PELVI-CALYCEAL SYSTEMS: Compact.

NODES: Not enlarged. FLUID: Nil significant.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest

normal.

PROSTATE: Prostate is normal in size, shape and echotexture. It measures 28 x 23 x 22 mm with volume 7 cc.

Rest normal.

SEMINAL VESICLES: Normal.

BOWEL: Visualized bowel loops appear normal.

#### **IMPRESSION**

-Diffuse grade I fatty infiltration in liver.

-Bilateral raised renal cortical echotexture (ADV:RFT correlation)

This report is subject to the A

Recommend clinical correlation.

Dr. Monica Shekhawat MBBS, DNB

**CONSULTANT RADIOLOGIST** 

Maria.

\*\*\*\*\*End Of Report\*\*\*\*\*





NAME	MR Digamber Kumar SOLANKI	STUDY DATE	24/02/2024 9:47AM
AGE / SEX	44 y / M	HOSPITAL NO.	MH011725749
ACCESSION NO.	R6938868	MODALITY	CR
REPORTED ON	24/02/2024 10:37AM	REFERRED BY	HEALTH CHECK MGD

#### XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal. TRACHEA: Normal. CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal. HEART: Normal.

RIGHT HEART BORDER: Normal. LEFT HEART BORDER: Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Normal.

THORACIC SPINE: Normal.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

#### IMPRESSION:

-No significant abnormality seen.

Please correlate clinically

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

**CONSULTANT RADIOLOGIST** 

\*\*\*\*\*End Of Report\*\*\*\*





Name

MR DIGAMBER SOLANKI

Age

44 Yr(s) Sex :Male

**Registration No** 

MH011725749

Lab No

202402004060

Patient Episode

H18000001830

**Collection Date:** 

24 Feb 2024 09:38

Referred By

HEALTH CHECK MGD

Reporting Date :

25 Feb 2024 13:11

**Receiving Date** 

: 24 Feb 2024 09:38

#### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

#### THYROID PROFILE, Serum

T3 - Triiodothyronine (ELFA)	1.150	ng/ml	[0.610-1.630]
T4 - Thyroxine (ELFA)	6.340	ug/ dl	[4.680-9.360]
Thyroid Stimulating Hormone	1.900	µIU/mL	[0.250-5.000]

#### NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page1 of 3





Name

MR DIGAMBER SOLANKI

Age

44 Yr(s) Sex :Male

Registration No

: MH011725749

Lab No

202402004060

**Patient Episode** 

: H18000001830

**Collection Date:** 

24 Feb 2024 09:38

Referred By

: HEALTH CHECK MGD

**Reporting Date:** 25 Feb 2024 13:10

**Receiving Date** 

: 24 Feb 2024 09:38

#### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

PROSTATE SPECIFIC ANTIGEN (PSA-Total):

0.620

ng/mL

[<2.500]

Method : ELFA

Note :1. This is a recommended test for detection of prostate cancer along with Digital Recta Examination (DRE) in males above 50 years of age

damage caused by BPH, prostatitis, or prostate cancer may increase circulating PSA levels.

- 2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
- 3. PSA levels may appear consistently elevated / depressed due to the interference by hetero antibodies & nonspecific protein binding
- 4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massag indwelling catheterization, and ultrasonography and needle biopsy of prostate is not recomme as they falsely elevate levels
- 5. PSA values regardless of levels should not be interpreted as absolute evidence of the pre or absence of disease. All values should be correlated with clinical findings and results of other investigations
- 6. Sites of Non prostatic PSA production are breast epithelium, salivary glands, peri urethral
  - & anal glands, cells of male urethra && breast mil
  - 7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity

#### Recommended Testing Intervals

- \* Pre-operatively (Baseline)
- \* 2-4 days post-operatively
- \* Prior to discharge from hospital
- \* Monthly follow-up if levels are high or show a rising trend

Page 2 of 3





Name

MR DIGAMBER SOLANKI

Age

44 Yr(s) Sex :Male

**Registration No** 

MH011725749

Lab No

202402004060

**Patient Episode** 

H18000001830

**Collection Date:** 

24 Feb 2024 09:38

Referred By

HEALTH CHECK MGD

**Reporting Date:** 25 Feb 2024 13:06

**Receiving Date** 

: 24 Feb 2024 09:38

**BLOOD BANK** 

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

O Rh(D) Positive

#### Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate /

-----END OF REPORT------

Page 3 of 3

NOTE:

# - Abnormal Values

Dr. Charu Agarwal Consultant Pathologist





Name

: MR DIGAMBER SOLANKI

**Registration No** 

: MH011725749

Patient Episode

: H18000001830

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 24 Feb 2024 09:38

Age

44 Yr(s) Sex :Male

Lab No

202402004060

**Collection Date:** 

24 Feb 2024 09:38

Reporting Date:

24 Feb 2024 12:44

#### HAEMATOLOGY

TEST	RESULT	UNIT BIOLOGIC	CAL REFERENCE INTERVAL
COMPLETE BLOOD COUNT (AUTOMA	TED)	SPECIMEN-EDTA Whole	Blood
RBC COUNT (IMPEDENCE) HEMOGLOBIN Method:cyanide free SLS-colo	5.31 15.6 rimetry	millions/cumm g/dl	[4.50-5.50] [13.0-17.0]
HEMATOCRIT (CALCULATED) MCV (DERIVED) MCH (CALCULATED) MCHC(CALCULATED) RDW CV% (DERIVED) Platelet count Method: Electrical Impedance MPV(DERIVED)	47.6 89.6 29.4 32.8 <b>14.7</b> # 176	% fL pg g/dl % x 10 <sup>3</sup> cells/cumm	[40.0-50.0] [83.0-101.0] [25.0-32.0] [31.5-34.5] [11.6-14.0] [150-410]
WBC COUNT(TC)(IMPEDENCE) DIFFERENTIAL COUNT (VCS TECHNOLOGY/MICROSCOPY)	6.01	x 10 <sup>3</sup> cells/cumm	[4.00-10.00]
Neutrophils Lymphocytes Monocytes Eosinophils Basophils	51.0 40.0 6.0 3.0 0.0	00 00 00 00 00	[40.0-80.0] [20.0-40.0] [2.0-10.0] [1.0-6.0] [0.0-2.0]
ESR	10.0	mm/1sthour	-0.0]

Page1 of 8







Name

: MR DIGAMBER SOLANKI

**Registration No** 

: MH011725749

**Patient Episode** 

: H18000001830

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 24 Feb 2024 15:49

Age

44 Yr(s) Sex :Male

Lab No

202402004060

**Collection Date:** 

24 Feb 2024 15:49

Reporting Date:

25 Feb 2024 13:39

## **CLINICAL PATHOLOGY**

# ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

# MACROSCOPIC DESCRIPTION

Colour

PALE YELLOW

(Pale Yellow - Yellow)

Appearance

CLEAR

(4.6 - 8.0)

Reaction[pH] Specific Gravity

5.0 1.005

(1.003 - 1.035)

# CHEMICAL EXAMINATION

Protein/Albumin

Negative

(NEGATIVE)

Glucose

NIL

(NIL)

Ketone Bodies

Negative

(NEGATIVE)

Urobilinogen

NORMAL

(NORMAL)

# MICROSCOPIC EXAMINATION (Automated/Manual)

Pus Cells

2-3/hpf

**RBC** 

0-1/hpf

(0-5/hpf)(0-2/hpf)

Epithelial Cells

1-2

/hpf

CASTS

NIL

NIL

Crystals Bacteria

NIL

OTHERS

NIL

Page 2 of 8







Name

: MR DIGAMBER SOLANKI

Registration No

: MH011725749

Patient Episode

: H18000001830

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 24 Feb 2024 09:38

Age

44 Yr(s) Sex :Male

Lab No

202402004060

**Collection Date:** 

24 Feb 2024 09:38

Reporting Date:

25 Feb 2024 13:29

**BIOCHEMISTRY** 

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

Method: HPLC

HbA1c (Glycosylated Hemoglobin)

5.9 #

[0.0-5.6]

As per American Diabetes Association (ADA

HbA1c in %

Non diabetic adults >= 18 years <5.7

Prediabetes (At Risk )5.7-6.4 Diagnosing Diabetes >= 6.5

Estimated Average Glucose (eAG)

123

mg/dl

Comments : HbAlc provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control.

# Serum LIPID PROFILE

	Serum TOTAL CHOLESTEROL Method:Oxidase,esterase, peroxide	182	mg/dl	[<200]
	TRIGLYCERIDES (GPO/POD)	110	mg/dl	Moderate risk:200-239 High risk:>240 [<150]
				Borderline high:151-199
	HDL- CHOLESTEROL		2 3	High: 200 - 499
	Method: Enzymatic Immunoimbibili	58.0	mg/dl	Very high:>500 [35.0-65.0]
	VLDL- CHOLESTEROL (Calculated) CHOLESTEROL, LDL, CALCULATED	22 102.0	mg/dl mg/dl	[0-35] [<120.0]
A)	pove optimal-100-129			Near/

Borderline High: 130-159 High Risk:160-189

Page 3 of 8





Name

: MR DIGAMBER SOLANKI

**Registration No** 

: MH011725749

Patient Episode

: H18000001830

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 24 Feb 2024 09:38

Age

44 Yr(s) Sex :Male

Lab No

202402004060

**Collection Date:** 

24 Feb 2024 09:38

Reporting Date:

24 Feb 2024 12:16

**BIOCHEMISTRY** 

3.1

TEST
T.Chol/HDL.Chol ratio(Calculated)

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

<4.0 Optimal

4.0-5.0 Borderline

>6 High Risk

LDL.CHOL/HDL.CHOL Ratio(Calculated)

1 8

<3 Optimal

3-4 Borderline

>6 High Risk

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis

#### KIDNEY PROFILE

Specimen: Serum			
UREA Method: GLDH, Kinatic assay	18.8	mg/dl	[15.0-40.0]
BUN, BLOOD UREA NITROGEN Method: Calculated	8.8	mg/dl	[8.0-20.0]
CREATININE, SERUM  Method: Jaffe rate-IDMS Standardization	0.83	mg/dl	[0.70-1.20]
URIC ACID Method:uricase PAP	5.8	mg/dl	[4.0-8.5]
	139.00	mmol/L	[136.00-144.00]
POTASSIUM, SERUM SERUM CHLORIDE Method: ISE Indirect	4.96 107.3	mmol/L mmol/L	[3.60-5.10] [101.0-111.0]

Page 4 of 8





Name

: MR DIGAMBER SOLANKI

Registration No

: MH011725749

Patient Episode

: H18000001830

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 24 Feb 2024 09:38

Age

44 Yr(s) Sex: Male

Lab No

202402004060

**Collection Date:** 

24 Feb 2024 09:38

Reporting Date:

24 Feb 2024 12:16

## **BIOCHEMISTRY**

		~	~ ~	
- 1	П	0.8	S	ľ

#### RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

eGFR (calculated)

107.0

ml/min/1.73sq.m

[>60.0]

Technical Note

eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis

# LIVER FUNCTION TEST

BILIRUBIN - TOTAL Method: D P D	0.59	mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.11	mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.48	mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM) Method: BIURET	7.10	gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.63	g/dl	[3.50-5.20]
GLOBULINS (SERUM) Method: Calculation	2.50	gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.87		[1.00-2.50]
AST(SGOT) (SERUM) Method: IFCC W/O P5P	26.00	U/L	[0.00-40.00]

Page 5 of 8





Name

: MR DIGAMBER SOLANKI

Age

44 Yr(s) Sex :Male

Registration No

: MH011725749

Lab No

202402004060

Patient Episode

: H18000001830

**Collection Date:** 

24 Feb 2024 09:38

Referred By

: HEALTH CHECK MGD

Reporting Date:

24 Feb 2024 12:16

**Receiving Date** 

: 24 Feb 2024 09:38

#### **BIOCHEMISTRY**

TEST	RESULT	UNIT	BIOLOGI	CAL REFERENCE INTERVAL
ALT(SGPT) (SERUM) Method: IFCC W/O P5P	41.20		U/L	[17.00-63.00]
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	63.0		IU/L	[32.0-91.0]
GGT	32.0		U/L	[7.0-50.0]

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page 6 of 8

-----END OF REPORT-----

Dr. Alka Dixit Vats Consultant Pathologist







Name

: MR DIGAMBER SOLANKI

Age

44 Yr(s) Sex :Male

**Registration No** 

: MH011725749

Lab No

202402004061

**Patient Episode** 

: H18000001830

Collection Date:

24 Feb 2024 09:38

Referred By

: HEALTH CHECK MGD

Reporting Date:

24 Feb 2024 12:17

**Receiving Date** 

: 24 Feb 2024 09:38

#### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

#### GLUCOSE-Fasting

Specimen: Plasma
GLUCOSE, FASTING (F)
Method: Hexokinase

99.0

mg/dl

[70.0-110.0]

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia),

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 7 of 8

-----END OF REPORT-----

Dr. Alka Dixit Vats Consultant Pathologist







Name

: MR DIGAMBER SOLANKI

Age

44 Yr(s) Sex :Male

**Registration No** 

: MH011725749

Lab No

202402004062

**Patient Episode** 

: H18000001830

**Collection Date:** 

24 Feb 2024 15:48

Referred By

: HEALTH CHECK MGD

Reporting Date:

25 Feb 2024 13:19

**Receiving Date** 

: 24 Feb 2024 15:48

**BIOCHEMISTRY** 

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

PLASMA GLUCOSE

Specimen: Plasma

GLUCOSE, POST PRANDIAL (PP), 2 HOURS

101.0

mg/dl

[80.0-140.0]

Method: Hexokinase

Note:

Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying, brisk glucose absorption , post exercise

Page 8 of 8

-----END OF REPORT-----

Dr. Charu Agarwal **Consultant Pathologist**